SpliceBio strengthens its Board along with raising €50m Series A financing co-led by UCB Ventures and Ysios Capital
– SPAIN, Barcelona – SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing co-led by UCB Ventures and existing shareholder Ysios Capital alongside new investors New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund, and existing shareholder Asabys Partners.…